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Abstract 
Background: Chemotherapy‑induced polyneuropathy (CIPN) is a common toxicity after chemotherapy, immu‑
nomodulatory drugs or proteasome inhibitors, which is difficult to treat and may also have impact on quality of life. 
The objective of the study was to evaluate whole‑body vibration (WBV) on the background of an integrated program 
(IP) including massage, passive mobilization and physical exercises on CIPN.
Patients and methods: In an exploratory phase‑2 study patients with CIPN (NCI CTC grade 2/3) were randomized 
for WBV plus IP (experimental) to IP alone (standard). 15 training sessions within 15 weeks were intended. As primary 
endpoint we used chair‑rising test (CRT) to assess physical fitness and coordination. In addition, locomotor and neu‑
rological tests and self‑assessment tools were performed.
Results: A total 131 patients with CIPN were randomized (standard, n = 65; experimental, n = 66). The median age 
was 60 (range 24–71) years; 44 patients had haematological neoplasms and 87 solid tumors. At baseline, all patients 
presented with an abnormal CRT. Fifteen (standard) and 22 (experimental) patients left the program due to progres‑
sion/relapse or concomitant disease. There was no significant difference in the proportion of patients with normal 
CRT (<10 s) at follow up between experimental (68%) and standard (56%) (p = 0.20). All patients experienced less 
symptoms and pain (p < 0.001) and had improved CRT (p < 0.001) over time. WBV was significantly associated with a 
higher reduction of time needed for CRT (p = 0.02) and significantly improved warm‑detection‑threshold comparing 
baseline to follow‑up assessment (p = 0.02).
Conclusion: Whole‑body vibration on the background of an IP may improve physical fitness and coordination in 
patients suffering from CIPN. Trial registration Retrospectively registered at http://www.iscrtn.com (ISRCTN 51361937) 
and http://www.clinicaltrials.gov (NCT02846844).
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Background
Chemotherapy induced polyneuropathy (CIPN) is a fre-
quent toxicity observed after chemotherapy [1], immu-
nomodulatory drugs or proteasome inhibitors [2], but 
may also occur with a lower incidence after other novel 
anti-cancer drugs such as arsenic trioxide [3] or bren-
tuximab [4]. The incidence of CIPN is estimated with 
38%, in particular if combination chemotherapy was 
administered [5]. However the incidence varies depend-
ing on chemotherapy-schedule, duration of exposure, 
and assessment methods [6, 7]. Clinically, CIPN is char-
acterized by sensory loss typically in a symmetrical, dis-
tal, “glove and stocking” distribution [8] that can lead 
to substantial interference with activities of daily life by 
severely disturbing fine motor skills, pain and insom-
nia. Furthermore, CIPN may be accompanied by motor 
and autonomic changes [9]. In a recently published 
meta-analysis including 4.179 patients a prevalence 
of CIPN was reported in the first month after chemo-
therapy of 68%, after 3 months of 60% and of 30% after 
6  months [1]. Prevention of CIPN has been studied in 
several trials but without leading to consistent results 
in subsequent meta-analyses [10, 11]. Neuroprotective 
therapeutic approaches using amifostine, glutathione, 
acetyl-l-carnitine, glutamine, calcium/magnesium infu-
sion, and gabapentin or pregabaline showed no or only 
little efficacy [12] as did adjuvant therapies with herbal 
medicine [13]. Treatment with electroacupuncture may 
be a therapeutic strategy for CIPN in patients with mul-
tiple myeloma. However, a randomized study is currently 
not available to confirm the results of the reported small 
phase-II study [14].
If CIPN is diagnosed during cancer therapy treatment 
options are limited; trials using antiepileptic or antide-
pressant drugs have been negative [15–18]. Recently, one 
double-blinded randomized trial was positive showing a 
reduction of chemotherapy-induced peripheral neuro-
pathic pain after 5  weeks of treatment with duloxetine 
[19].
CIPN heavily affects physical fitness by the severe con-
sequences of loss of peripheral somatosensory informa-
tion on human balance and locomotion [20, 21]. This 
observation prompted us to develop a stepwise training 
program with the aim to improve and specifically train 
skills necessary for daily life activities [22]. The program 
was composed of 15 sessions on a biweekly basis of two 
parts, (i) massage and passive mobilization in posture 
and transport layers to induce proprioceptive and tactile 
stimuli and (ii) gymnastics to improve physical fitness. 
A growing body of evidence indicates improvements of 
various neuromuscular parameters following whole-
body vibration (WBV), such as power, strength, move-
ment velocity, range of motion and in particular balance 
[23–26]. However, WBV alone did not yet show a clear 
benefit for patients with peripheral neuropathy [27]. We 
hypothesized that applying WBV after massage and pas-
sive mobilization in posture and transport layers may 
harness the potential benefits of WBV to patients with 
CIPN. Therefore, we conducted an up-front randomized 
explorative phase 2 trial to investigate whether the addi-
tion of WBV to our program has the potential to improve 
outcome in patients with CIPN.
Methods
Patients and study design
Written informed consent was obtained from all patients. 
The protocol was approved by the Ethics Review Com-
mittee. Cancer patients between 18 and 70  years of age 
suffering from solid or hematological neoplasms suf-
fering from CIPN grade II–III according to National 
Cancer Institute Common Toxicity Criteria (NCI CTC, 
version 3.0) and pathological chair-rising test (CRT) [28] 
(≥10  s) were eligible. Exclusion criteria were disability 
to perform the CRT at all, known psychiatric disorders, 
plasmatic coagulation disorders, thrombotic/thrombo-
embolic events within 6  months before randomization 
and severe neurological disorders like seizures. In this 
single center study, patients were randomly assigned (1:1) 
to the experimental (including WBV) or the standard 
arm. Randomization was carried out based on a prede-
fined list with blocks of 4.
Whole‑body vibration platform
The vibration platform Galileo-Fitness [29] (Novotec 
Medical GmbH, Germany) contains a seesaw plate with 
adjustable amplitude and frequency fixed at a right angle 
on an electrically customizable examination couch. The 
seesaw motion at high frequencies resulted in a high 
amount of stimulatory impulses to the legs applied dur-
ing one intervention, similar to the number of impulses 
received during 2–3 h of walk at regular speed [30].
Treatment
1st part
All patients received massage and passive mobilization 
in posture and transport layers [31] for 30 min per side. 
Keywords: Chemotherapy related peripheral neuropathy, Integrated training program, Whole body vibration 
training, Chemotherapy associated side effects
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Joints of the lower extremities were moved passively 
for warm-up and stretching of muscle groups in their 
degrees of freedom. The passive mobilization of the legs 
always started with the most distal joints (toes) moving 
gradually more proximally.
2nd part
Patients in the experimental arm received training with 
WBV. All WBV steps were applied according to indi-
vidual patients’ tolerability. In a warm-up time of 3 min, 
patients were treated with frequencies starting from 
9 Hz and increasing up to 13 Hz in a horizontal position 
of the examination couch (0° elevation). Afterwards, the 
position was changed starting with 30° elevation at a fre-
quency of 14 Hz and increasing to an elevation of 60°–90° 
at a frequency of 18 Hz (3 min). Thereafter, the position 
was changed in all patients to 90° elevation (up-right 
position) starting at a frequency of 19 Hz and increased 
to a frequency of 23  Hz (3  min). Finally, a cool-down 
phase (9 min) followed with lower frequencies of 9 Hz to 
13 Hz decreasing from 30° elevation to a lying position to 
protect patients from muscle soreness.
Patients randomized to the standard arm switched 
after part 1 immediately to part 3.
3rd part
Alternating training exercises with a focus on training of 
posture and transport movements were initiated includ-
ing 21 separate exercises (Additional file 1: Table S1).
All patients were invited to practice the exercises 
at home on a daily basis and asked to document their 
efforts. In addition, all patients were motivated to walk 
as frequently and long as possible. This was documented 
by a pedometer (OMRON Step Counter Walking style 
III; OMRON Healthcare Co., Ltd Kyoto, Japan) during 
the intervention period. Walking distance was recorded 
by counting steps cumulatively between the sessions and 
reported as steps per day.




All patients were assessed for severity of peripheral neu-
ropathy before, after 8 and 15 interventions and one 
month after the last intervention (follow-up) according 
to NCI-CTC scale by two investigators (S.S. and RFS). In 
addition, during the same visits all patients were asked to 
complete the Functional Assessment of Cancer Therapy/
Gynecologic Oncology Group neurotoxicity subscale 
(FACT/GOG-NTX) using the categories “not at all”, “a 
little bit”, “somewhat”, “quite a bit” and “very much”, and 
quality of life questionnaire (EORTC QLQ-C30, version 
3.0) with composed measures global status, function and 
symptom score as well as overall QoL [6, 7].
Physical examination
The physical examination including neurological assess-
ment was performed before the intervention, after 8 
and 15 sessions, as well as at follow up. The examination 
included patellar tendon reflex and Achilles tendon reflex 
at both sides, quantitative evaluation of pallesthesia by 
using a Rydel-Seiffer tuning fork (C64) with a scale from 
0/8 (worse) to 8/8 (best), discrimination between cold/
warm (Tipterm) and light touch and pinprick, respec-
tively [32].
Chair‑rising test (CRT)
The test was performed as previously described [29]. 
Patients were asked to stand up from a standardized 
chair (height: 46 cm) with their arms crossed in front of 
the chest for five times as fast as possible. Normal values 
for the CRT were defined as  <10  s. For evaluation both 
a dichotomized (normal, abnormal) read-out as well as 
total time needed to complete the CRT in seconds were 
assessed.
Quantitative sensory testing (QST)
The quantitative sensory testing followed a standardized 
protocol [33]. Patient’s right foot was the test area and 
the face the reference area. This included the evaluation 
of the cold detection threshold (CDT), the warm detec-
tion threshold (WDT), the thermal sensory limen (TSL), 
the cold pain threshold (CPT), the heat pain threshold 
(HPT), the pressure pain threshold (PPT), the mechani-
cal pain threshold (MPT), the mechanical pain sensitivity 
(MPS), the wind-up ratio (WUR), the mechanical detec-
tion threshold (MDT) and the vibration detection thresh-
old. Person for QST assessment was blinded.
Statistical analysis
Paired comparisons of baseline variables according to 
randomization were performed by the Mann–Whitney 
test for continuous variables and by Fisher’s exact test 
for categorical variables. Correlations of continuous vari-
ables were assessed by Spearman’s rank correlation coef-
ficient. 95% confidence intervals (95% CI) were computed 
using 5000 bootstrap samples. The primary endpoint of 
the study was achievement of normal values (<10  s) in 
the CRT at follow-up. Based on previously reported data 
we assumed that 30% of patients in the standard arm will 
achieve a normal CRT after completion of the program. A 
clinically meaningful improvement was defined as a pro-
portion of 60% of patients with normal CRT after comple-
tion of the program. To show this with an alpha of 5% and 
a power of 90% 122 patients had to be randomized in a 
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1:1 ratio. Secondary endpoints were time in seconds nec-
essary to complete the CRT, severity of peripheral neu-
ropathy categorized according to NCI-CTC and FACT/
GOG-NTX, quality of life with global, functional and 
symptom score as well as global QoL, absence or presence 
of Achilles and patellar tendon reflexes, and all dimen-
sions of quantitative sensory testing. Secondary endpoints 
were analyzed by comparing differences between baseline 
and subsequent assessment time points using one -sample 
Wilcoxon signed rank test and Mann–Whitney test. The 
secondary endpoints were additionally analyzed using 
generalized estimating equations for longitudinal assess-
ments. With a GEE model for the CRT using a lognormal 
distribution for rising times in seconds and assuming a 
time dependency of a first order autoregressive process 
for the four time points was set up.
All statistical analyses were performed with the statisti-
cal software environment R, version 3.2.1, and geepack, 
version 1.2-0, and lsmeans, version 2.23 [34].
Results
Baseline characteristics
A total of 131 patients (n  =  63 male, n  =  68 female) 
were randomized into the experimental arm (n  =  66 
patients) and the standard arm (n  =  65 patients). The 
CONSORT diagram is displayed in Fig.  1. The patient 
characteristics according to treatment arm were well bal-
anced except time since last and time since first chemo-
therapy with longer time intervals in the experimental 
arm (Table 1). Overall median age was 60.5 years (range 
24–71 years), two-thirds of the patients were diagnosed 
with solid tumors mostly being of stage III/IV accord-
ing to WHO classification and one-third with hemato-
logical malignancies. All patients developed CIPN after 
intensive chemotherapy, 97% after combination chemo-
therapy and 35% with additional radiotherapy. Accord-
ing to NCI-CTC CIPN was categorized as grade III in 
52% and grade II in 48%. At the time of study entry 27% 
(36/131) of the patients had active treatment (to control 
Fig. 1 CONSORT diagram. This figure shows the clinical course after randomization. N = 66 patients were randomized to the experimental arm and 
n = 65 patients to the standard arm. N = 44 in the experimental arm and n = 50 in the standard arm reached the follow up period. R randomiza‑
tion, IC informed consent, n number, FU follow up, WBV whole‑body vibration therapy
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Table 1 Patient characteristics at baseline according to treatment arm
WBV whole-body vibration therapy, WHO World Health Organization, NCI CTC National Cancer Institute Common Toxicity Criteria
a Single agent chemotherapy; experimental arm, n = 2, arsenic trioxide, radioiodine therapy; standard arm, n = 2, cladribine, trastuzumab
Treatment with WBV Treatment without WBV p value
N = 66 N = 65
Sex, male/female 29/37 34/31 0.38
Age, years, median (Range) 59 (28–70) 62 (24–71) 0.10
Diagnosis, no. (%) 0.85
 Hematological malignancies 23 (35) 21(32)
  Multiple myeloma 8 (12) 11 (17)
  Lymphomas 10 (15) 7 (11)
  Leukemias 5 (7.5) 3 (5)
 Solid tumors 43 (65) 44 (68)
  Colorectal 13 (20) 12 (18.5)
  Lung 5 (7.5) 3 (4.5)
  Esophageal/gastric 2 (3) 10 (15)
  Breast/ovarian 13 (20) 12 (18.5)
  Other 7 (10.5) 4 (6)
Disease state (excl. leukemias)
 Multiple myeloma (Salmon‑Durie)
  I 3
  II 4 1
  III 4 7
 Lymphoma (Ann‑Arbor)
  I 1
  II 1
  III 4 1
  IV 4 6
 Solid tumors (WHO)
  I 2 4
  II 8 10
  III 19 10
  IV 14 20
Pretreatment, no. (%)
 Radiotherapy 28 (42%) 18 (28%) 0.10
 Chemotherapy 66 (100%) 65 (100%)
 Combination chemotherapya 64 (97%) 63 (97%) 0.99
 Platinum‑based 27 (41%) 35 (54%) 0.16
 Taxane‑based 22 (33%) 17 (26%) 0.45
 Vinca alkaloids 9 (14%) 8 (12%) 0.99
 Bortezomib 6 (9%) 7 (11%) 0.78
Time since last chemotherapy
 In months, median (range) 2 (0–98) 0 (0–51) 0.07
Time since first chemotherapy
  In months, median (range) 19 (4–156) 9 (2–180) 0.005
Treatment related neuropathy
 NCI‑CTC
  Grade II 28 (42%) 35 (54%) 0.22
  Grade III 38 (58%) 30 (46%)
  Active treatment to control pain, No. (%) 15 (23%) 21 (32) 0.24
  Chemotherapy during study No. (%) 25 (38%) 34 (51%) 0.12
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CIPN induced pain). According to FACT/GOG-NTX the 
patients mainly reported substantial (comprising the cat-
egories “somewhat”, “quite a bit”, “very much”) tingling as 
well as discomfort in the feet (97 and 98%, respectively) 
which corresponded to the perception of a severely low 
muscle mass (86%) and a general severe weakness (74%), 
whereas symptoms in the upper extremities were rare 
(Additional file 2: Table S2). The QoL assessed with the 
QLQ-C30 revealed before the start of any intervention 
a median global status of 50% (range 0–83%), a median 
function-related QoL of 49% (range 9–91%) a median 
symptom-oriented QoL of 62% (range 21–92%) and a 
median overall QoL of 53% (16–90%) without differ-
ences in the treatment arms. On neurological examina-
tion Achilles tendon reflexes were absent bilaterally in 
58% of participants while absent patellar reflexes bilat-
erally in 42% without differences in the treatment arms. 
Quantitative sensory testing revealed a severely impaired 
WDT and CDT of +12.3  °C (range 1.1–18  °C) and 
−7.8  °C (range −32 to −1.7  °C), respectively, as well as 
MDT of 13.9 mN (0.2–724 mN). All patients had abnor-
mal CRT results (≥10  s). At baseline higher WDT was 
in trend associated with longer time needed to complete 
the CRT (rho = 0.16, 95% CI = [−0.03, 0.34]), which was 
not the case for the CDT and MDT (rho = −0.07, 95% 
CI =  [−0.25, 0.11] and rho = −0.06, 95% CI =  [−0.24, 
0.12], respectively).
Treatment phase
All patients started with the first intervention, 66 in the 
experimental arm with WBV and 65 in the standard 
arm. Within the first 8 sessions 12 (experimental) and 7 
(standard), terminated the program early (Fig. 1) due to 
withdrawal of the IC (n = 6), progress of the underlying 
malignant disease (n = 4), surgery (n = 2), death (n = 2) 
or for other reasons (n = 5). Thus 54 and 58 patients were 
evaluated after 8 treatment sessions. Further 8 patients, 4 
in each arm, terminated the program during the follow-
ing 7 treatment sessions resulting in 50 and 54 patients 
being evaluated after 15 treatment session. Further test-
ing at follow-up was performed in 44 (experimental arm) 
and 50 (standard arm) patients, respectively. Thus 67% 
(44/66) and 77% (50/65) of the patients completed the 
whole program in the experimental and standard arm, 
respectively.
Evaluation of the primary endpoint
At baseline all patients had a CRT with pathological val-
ues with  ≥10  s (median, 14  s; range 10–55  s) without 
significant difference in the treatment arms (p  =  0.20). 
During the treatment course the proportion of patients 
with a normal CRT significantly increased to 19% (17% 
standard, 20% experimental) after 8 sessions, 51% (56% 
standard, 46% experimental) after 15 sessions and 62% 
(56% standard, 68% experimental) at follow-up with-
out significant differences between the two arms at the 
respective time points (p  =  0.40, p  =  0.30, p  =  0.20, 
respectively). Thus, in contrast to our initial sample size 
planning the proportion of patients with normal values 
to complete the CRT was higher in the standard arm as 
expected. However, the reduction of time needed to com-
plete the CRT from baseline to follow-up assessment 
was significantly higher in the experimental arm (−5.5 s) 
compared to the standard arm (−4.0 s) (Fig. 2).
Evaluation of the secondary endpoints
During treatment and at follow-up the proportion of 
patients with impairment in the lower extremity accord-
ing the FACT/GOG-NTX categories “tingling” as well 
as “discomfort” in the feet were significantly (p < 0.001, 
p < 0.001) reduced from 97 to 81% and 98 to 71%, respec-
tively. This was in trend more frequently observed for the 
category “discomfort in the feet” in the experimental arm 
compared to the standard arm after 15 treatment ses-
sions and at follow-up (Additional file  2: Table S2). All 
other categories evaluated according the FACT/GOG-
NTX indicated again a significant improvement over 
time but no difference between study arms. Similarly, 
global status, functional and symptoms score as well as 
overall QoL (EORTC QLQ C30) improved over time but 
again without differences between the study arms (Addi-
tional file 2: Table S2). The recorded walking distance per 
day did not increase overall with any difference between 
the study arms.
During treatment and at follow-up a marked improve-
ment of the neurological reflex status in the lower 
extremities occurred, with consistently lower propor-
tions of patients with absent Achilles and patellar tendon 
reflexes. However, this difference did not reach statistical 
significance (Additional file 2: Table S2).
Quantitative sensory testing before the intervention 
and after completion of the program revealed a sig-
nificant reduction in the WDT in the experimental arm 
compared to the standard arm (paired rank order test, 
p = 0.03), whereas in the other assessed qualities no rel-
evant improvement was noted overall and between the 
study arms (Fig. 3, Table 2). Consistently, the GEE model 
for longitudinal assessments revealed that the WDT was 
reduced significantly over time and in particular in the 
experimental arm (interaction test, p = 0.04).
Multivariable analysis for longitudinal assessments
An exploratory analysis on the time needed to complete 
the CRT measured in seconds including all assessments 
from baseline to follow-up, treatment arm and initial 
WDT using a GEE model for longitudinal assessments 
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revealed that a baseline higher WDT was associated with 
a longer time needed for the CRT over time (estimate, 
0.015, standard error [SE], 0.006, p = 0.02), that the time 
needed for the CRT decreased significantly over time 
(p < 0.001), and that patients treated in experimental arm 
had a significantly higher reduction in the time needed 
for the CRT compared to those treated in standard arm 
(interaction test, p = 0.03), (Fig. 4).
Fig. 2 Distribution of individual absolute time‑differences in seconds between baseline and follow‑up needed to complete the CRT according to 
randomization (black, experimental arm with whole‑body vibration therapy; white, standard arm). Arrows indicate patients with normal values for 
completion of the CRT at follow‑up. Patients with no change were marked by a ‘*’ (experimental arm) and ‘#’ (standard arm), respectively. CRT chair‑
rising test
Fig. 3 Distribution of individual absolute differences in degrees Celsius between baseline and completed program of the warm detection thresh‑
old (WDT) assessed with quantitative sensory testing according to randomization (black, experimental arm with whole‑body vibration therapy; 
white, standard arm). Patients with no or very little change were marked by a ‘*’ (experimental arm) and ‘#’ (standard arm), respectively. WDT warm 
detection threshold
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Discussion
The aim of our study was to evaluate the relative impact 
of WBV within a structured training program to treat 
CIPN. Overall, the addition of WBV resulted in a sig-
nificant reduction in time needed to complete the CRT 
(Fig.  2) indicating better fitness and balance as well 
Table 2 Quantitative sensory testing over time
WBV whole-body vibration therapy, °c degree Celsius, mN Millinewton, WDT warm detection threshold, CDT cold detection threshold, HPT heat pain threshold, MDT 
mechanical detection threshold
Total Treatment with WBV Treatment without WBV p value
C‑fibers
 Warm detection threshold (WDT)
  Baseline n = 119 n = 55 n = 64
   Test‑area °C (range) 12.3 (1.1 to 18.0) 12.6 (1.3 to 18.0) 12.1 (1.1 to 18.0) 0.49
   Reference‑area °C (range) 1.2 (0.5 to 22.8) 1.2 (0.5 to 22.8) 1.2 (0.5 to 17.6) 0.45
After 15 Interventions n = 87 n = 40 n = 47
   Test‑area °C (range) 10.4 (1.3 to 18.0) 9.5 (1.3 to 18.0) 11.0 (2.7 to 18.0) 0.09
   Reference‑area °C (range) 1.3 (0.5 to 15.8) 1.3 (0.5 to 8.8) 1.3 (0.5 to 15.8) 0.72
Difference n = 87 n = 40 n = 47
   Test‑area Δ °C (range) −0.7 (−13.1 to 16.9) −1.1 (−13.1 to 6.2) −0.1 (−10.0 to 16.9) 0.03
   Reference‑area Δ °C (range) 0.0 (−22.2 to 2.2) 0.0 (−22.2 to 2.2) 0.0 (−16.5 to 2.0) 0.35
 Heat pain threshold (HPT)
  Baseline n = 129 n = 55 n = 64
   Test‑area °C (range) 48.6 (34.9 to 50.0) 48.7 (34.9 to 50.0) 48.3 (39.2 to 50.0) 0.39
   Reference‑area °C (range) 44.7 (33.8 to 50.0) 44.7 (33.9 to 49.5) 44.7 (33.8 to 50.0) 0.36
After 15 Interventions n = 87 n = 40 n = 47
   Test‑area °C (range) 48.5 (37.4 to 50.0) 48.1 (37.4 to 50.0) 48.7 (39.9 to 50.0) 0.47
   Reference‑area °C (range) 44.9 (33.8 to 50.0) 44.8 (33.9 to 50.0) 45.2 (33.8 to 50.0) 0.48
Difference n = 85 n = 38 n = 47
   Test‑area Δ °C (range) 0.0 (−7.2 to 8.94) −0.04 (−3.93 to 3.57) 0.0 (−3.34 to 3.60) 0.54
   Reference‑area Δ °C (range) 0.0 (−4.4 to 0.6) 0.0 (−0.12 to 4.23) 0.0 (−0.51 to 2.12) 0.92
Aδ‑fibers
 Cold detection threshold (CDT)
  Baseline n = 110 n = 56 n = 64
   Test‑area °C (range) −7.8 (−32.0 to 1.7) −7.6 (−32.0 to −1.7) −8.4 (−32.0 to −1.9) 0.35
   Reference‑area °C (range) −1.2 (−21.9 to 0.5) −1.1 (−9.7 to −0.5) −1.4 (‑21.9 to −0.5) 0.08
After 15 Interventions n = 88 n = 41 n = 47
   Test‑area °C (range) −6.8 (−32.0 to −1.3) −6.6 (−32.0 to −1.3) −6.9 (−32.0 to −1.6) 0.36
   Reference‑area °C (range) −1.3 (−21.9 to 0.5) −1.1 (−6.8 to −0.47) −1.4 (−21.9 to −0.5) 0.12
Difference n = 85 n = 38 n = 47
   Test‑area Δ °C (range) 0.7 (−11.1 to 26.9) 1.1 (−10.1 to 24.9) 0.7 (−11.1 to 26.9) 0.46
   Reference‑area Δ °C (range) 0.0 (−4.0 to 6.7) 0.0 −0.3 to 6.7) 0.0 (4.0 to 3.9) 0.23
Aβ‑fibers
 Mechanical detection threshold (MDT)
  Baseline n = 110 n = 56 n = 64
   Test‑area mN (range) 13.9 (0.2 to 724) 12.6 (0.9 to 724) 16.6 (0.2 to 223) 0.44
   Reference‑area mN (range) 0.2 (0.2 to 6.1) 0.2 (0.2 to 6.1) 0.2 (0.2 to 4.6) 0.20
After 15 Interventions n = 88 n = 41 n = 47
   Test‑area mN (range) 17.8 (0.3 to 724) 19.7 (0.3 to 724) 17.2 (1.3 to 724) 0.73
   Reference‑area mN (range) 0.2 (0.2 to 11.3) 0.2 (0.2 to 11.3) 0.2 (0.2 to 4.6) 0.26
Difference n = 85 n = 38 n = 47
   Test‑area mN (range) 0.0 (−174 to 501) 0.8 (−174 to 207) −3.4 (−105 to 501) 0.35
   Reference‑area mN (range) 0.0 (−0.5 to 4.8) 0.0 (−0.02 to 4.8) 0.0 (−0.5 to 0.2) 0.94
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as a significant reduced WDT (Fig.  3) as read out for 
improved sensory function after completion of the 
program.
All 131 patients were treated with massage, mobiliza-
tion as well as physical exercises and were randomized 
for the addition of WBV (n = 66) during biweekly treat-
ment sessions. N = 94 reached follow up after 15 treat-
ment sessions. As primary endpoint we used the CRT 
as a surrogate marker for physical fitness and posture 
balance; secondary endpoints were Qol, the FACT/
GOG-NTX, blinded quantitative sensory testing and 
physical examination. Based on a recently published 
meta-analysis a prevalence of CIPN as high as 68% in 
the first month after chemotherapy was reported with 
a resolution of symptoms in only 12% of the affected 
patients after 3 months [1] and persistence of symptoms 
up to 11  years after chemotherapy [35]. In contrast, in 
our study all patients experienced marked improve-
ment in physical fitness and posture balance with more 
than 50% of the patients with a normal CRT, a marked 
improvement in quality of life based on symptoms and 
function scores assessed by EORTC QLQ-C30 as well as 
an improved tendon reflex status. However, still most of 
our patients suffered from tingling and discomfort in the 
feet as measured with the FACT/GOG-NTX. Although 
our study was not randomized versus observation, the 
overall results suggest an important beneficial impact 
of massage, mobilization as well as physical exercises in 
the management of CIPN. Furthermore, WBV applied in 
addition to this program seems to further improve out-
come with in trend less patients suffering from discom-
fort in the feet, significantly better performance in the 
CRT and an improved WDT after completion of all train-
ing sessions. Compared to attempts with medical therapy 
using anti-epileptics or antidepressants [15–18], anti-oxi-
dative and other neuroprotective drugs [11, 12], as well 
as herbal medicine [13], our approach showed effects 
measured by objective endpoints including the CRT and 
the WDT as well as in subjective endpoints measured by 
the FACT/GOG-NTX. Interestingly, electroacupuncture 
also showed an improvement of CIPN measured with the 
FACT/GOG-NTX scale [14]. Due to the heterogeneity of 
applied chemotherapeutic agents and their combinations 
as well as limited sample size, we were not able to per-
form meaningful subset-analyses for selected agents or 
combinations. However, in our initial sample size calcula-
tion we underestimated the effect of massage, mobiliza-
tion as well as physical exercises alone with a normalized 
CRT in 56% of our patients after completion of the pro-
gram in the standard arm and thus we were not able to 
show the initially projected improvement. Nevertheless, 
the reported results showed an improvement in objec-
tive and subjective endpoints. CIPN affects mostly large 
Aβ myelinated fibers and unmyelinated C fibers [36]. The 
function of the unmyelinated C-fibers can be estimated 
by use of the WDT [33]. By the addition of WBV, we 
observed a reduction of the WDT by in median 1.1  °C 
in the experimental arm compared to 0.1  °C (p =  0.03) 
in the standard arm (Table 2). To our knowledge this is 
the first time such a finding has been described. A higher 
WDT was associated with a longer time needed for the 
CRT and significantly impacted the time needed for the 
CRT in our multivariable model with repeated measure-
ments. Thus the WDT may be an early read-out of an 
improvement in CIPN.
In conclusion, the treatment of CIPN with a program 
including massage, mobilization as well as physical exer-
cises and WBV had a significantly and clinically relevant 
beneficial impact on symptoms relieve, physical fitness 
and sensory function. The integration of this program 
into daily clinical practice is desirable but will require a 
structured prospective assessment of CIPN and impor-
tantly a specialized education of nursing staff.
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